Expression of DcR3 and Its Effects in Kaposi’s Sarcoma-Associated Herpesvirus-Infected Human Endothelial Cells

Seungmin Yoo  Jaehyuk Jang  Sil Kim  Haewol Cho  Myung-Shin Lee

Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, South Korea

Introduction

Kaposi’s sarcoma (KS) is a vascular tumor, primarily consisting of proliferating spindle-shaped endothelial cells and infiltrates of inflammatory cells [1]. The human gammaherpesvirus KS-associated herpesvirus (KSHV), which was initially identified in a KS lesion from an AIDS patient [2], has been convincingly linked to the development of all four clinical forms of KS, including classical KS, AIDS-related KS, African endemic KS, and immunosuppressed post-transplant KS [3]. The genome of KSHV and its encoded gene products are detected in the majority of spindle cells and sporadically in monocytes, macrophages, keratinocytes, and lymphocytes in KS tumors, but not in adjacent tissues or control tissues from patients without KS. KSHV has also been associated with other lymphoproliferative diseases, including primary effusion lymphoma and multicentric Castleman’s disease.

Decoy receptor 3 (DcR3) is a lymphotoxin-like member of the tumor necrotic factor receptor superfamily. In addition to acting as the decoy receptor for Fas ligand, LIGHT and TL1A, DcR3 can neutralize the biological effect of TL1A by inhibiting the TL1A-DR3 interaction in human endothelial cells. The present study examined the expression of DcR3 in human endothelial cells and its effect during the early stages of KSHV infection.

Methods

The expression of DcR3 was assessed using real-time RT-PCR and ELISA in human umbilical cord vein endothelial cells (HUVECs) infected with KSHV. Cell proliferation and apoptosis of KSHV-infected HUVECs were assessed after treatment of infected cells with an anti-DcR3 antibody or recombinant human TL1A.

Results

DcR3 expression was induced during the early phase of KSHV infection. Inhibition of DcR3 with anti-DcR3 antibodies or recombinant human TL1A-induced apoptosis in KSHV-infected HUVECs.

Conclusion

The expression of DcR3 plays an important role in the prevention of apoptosis in HUVECs during the early phases of KSHV infection, thus ensuring the successful establishment and maintenance of the viral infection.

Key Words
Kaposi’s sarcoma-associated herpesvirus · Kaposi’s sarcoma · DcR3 · TL1A

Abstract

Objective: Kaposi’s sarcoma-associated herpesvirus (KSHV) is classified as a gamma-herpesvirus and it causes Kaposi’s sarcoma in patients infected with the human immunodeficiency virus (HIV). Decoy receptor 3 (DcR3) is known as a decoy receptor for Fas ligand, LIGHT and TL1A and it can neutralize the biological effect of TL1A by inhibiting the TL1A-DR3 interaction in human endothelial cells. The present study examined the expression of DcR3 in human endothelial cells and its effect during the early stages of KSHV infection.

Methods: The expression of DcR3 was assessed using real-time RT-PCR and ELISA in human umbilical cord vein endothelial cells (HUVECs) infected with KSHV. Cell proliferation and apoptosis of KSHV-infected HUVECs were assessed after treatment of infected cells with an anti-DcR3 antibody or recombinant human TL1A.

Results: DcR3 expression was induced during the early phase of KSHV infection. Inhibition of DcR3 with anti-DcR3 antibodies or recombinant human TL1A-induced apoptosis in KSHV-infected HUVECs.

Conclusion: The expression of DcR3 plays an important role in the prevention of apoptosis in HUVECs during the early phases of KSHV infection, thus ensuring the successful establishment and maintenance of the viral infection.
nant tumors, such as those of the lung, colon, stomach, pancreas, and from gliomas [6–9]. Moreover, high serum levels of DcR3 have been detected in many cancer patients [10]. The overexpression of DcR3 may, therefore, constitute a relative advantage for tumor growth and survival. Supporting this notion, tumor cells engineered to release high amounts of DcR3 are protected from apoptotic cell death and chemotaxis, resulting in decreased immune cell infiltration in glioma xenografts [11].

DcR3 is upregulated in EBV-infected cells or EBV-associated lymphomas [12, 13]. However, information on DcR3 levels in other human gammaherpesvirus-infected cells is limited. The aim of the present study was to investigate the expression and function of DcR3 in the KSHV infection of susceptible target cells such as human umbilical cord vein endothelial cells (HUVECs). The induction of cell proliferation, migration, tube formation and angiogenesis in HUVECs by DcR3 through interference with TL1A function [4] suggests that DcR3 could have a similar effect in KSHV-infected HUVECs when it is upregulated after infection. TL1A or TNF superfamily member 15 (TNFSF15) is also expressed in endothelial cells and soluble TL1A fragments can induce apoptosis of endothelial cells in an autocrine manner [14, 15]. In the present study, DcR3 expression was shown to increase in the immediate early phase of viral infection and to play a role in the inhibition of apoptosis in KSHV-infected HUVECs.

Materials and Methods

Cells and Reagents

Primary cultures of human umbilical vein endothelial cells (HUVEC; Clonetics, San Diego, Calif., USA) were subcultured in endothelial cell growth medium (EGM-2 BulletKit; Clonetics) containing human endothelial growth factor, human fibroblast growth factor B, vascular endothelial growth factor, ascorbic acid, hydrocortisone, long R3-IGF-1, and heparin as described by the manufacturer. BCBL-1 and 293 cells harboring the recombinant KSHV, BAC36, have been described previously [16, 17]. Anti-human DcR3 antibody and recombinant human TL1A were purchased from R&D systems (Minneapolis, Minn., USA).

Preparation and Infection of KSHV BAC36

The recombinant KSHV BAC36, containing a green fluorescent protein (GFP) cassette, was induced in BCBL-1 cells or 293T cells harboring BAC36 by treating the cells with 20 ng ml⁻¹ of tetradecanoyl phorbol acetate (TPA, Sigma, St. Louis, Mo., USA) for 3 days. The isolated virus was used to infect cells as described previously [18]. Infection was conducted by centrifugation at 2,500 g for 60 min with 5 μg ml⁻¹ of polybrene (Sigma Aldrich). Infectivity was estimated by examining GFP expression under an inverted fluorescence microscope.

Immunochemistry

Cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with phosphate-buffered saline containing 0.3% Triton X-100 for 5 min, and blocked with 5% bovine serum albumin (BSA). Cells were incubated with anti-ORF73 (Advanced Biotechnologies Inc., Columbia, Md., USA, 1:250) or anti-ORF59 (Advanced Biotechnologies Inc., 1:250) overnight at 4°C followed by incubation with rhodamine-labeled anti-rat antibody (KPL, UK) or rhodamine-labeled anti-mouse antibody (KPL, UK) for 30 min at room temperature. After washing, the sample was mounted with Vectashield® (Vector laboratories, Inc., Burlingame, Calif., USA) and stained with 4,6-diamidino-2-phenylindole (DAPI). Analyses were performed using a Nikon ECLIPSE E400 fluorescence microscope.

Flow Cytometry

KSHV-infected or mock-infected HUVECs were detached from the plate with 0.25% trypsin-EDTA, and flow cytometry was performed with a FACS Calibur flow cytometer. The data were analyzed with CellQuest Pro software (Becton Dickinson, Bedford, Mass., USA). Prior to analysis, all samples were gated to eliminate dead cells.

ELISA

The DcR3 concentration in cell-culture medium was analyzed with a human Decoy Receptor 3 ELISA kit (BioVendor Laboratory Medicine) according to the manufacturer’s instructions. The culture supernatant from 5 × 10⁵ culture (2 ml) cells was collected and stored at −70°C before use.

Real-Time RT-PCR

Total RNA from infected HUVECs was prepared with TRIzol reagent as recommended by the manufacturer (Sigma). Reverse transcription and quantitative PCR were conducted as described previously [18]. All samples, including a non-template control and internal glyceraldehyde 3-phosphate dehydrogenase (GAPDH) amplification controls, were examined in triplicate for each primer pair. Data analysis was carried out as described previously [15]. The primers used in this study were: DcR3_F650 5’-TCAATGTGCCAGGCTCTTC-3’, DcR3_R793 5’-GCCCTTTGATG-GAGATTGCC-3’, GAPDH_F6 5’-GAAGATGGTGATGGGATTTC-3’, GAPDH_R793 5’-GAAGATGGTGATGGGATTTC-3’, TL1A_F11541 5’-TTTGTTGGAGAAACACACACACAG-3’, TL1A_R11541 5’-CCGAATGTGACCTGGGAGTAAATG-3’, LIGHT_F420 5’-TGATACAAGCCGGAAGCT-3’, LIGHT_R420 5’-TTGGAGTAGATGTAGTAGC-3’. The primers were synthesized by GENOTECH (South Korea).

Cell Proliferation Assay and Apoptosis Assay

After viral infection, the viral supernatant was removed and culture media with anti-DcR3 antibody or recombinant human TL1A were added to each well. After incubation for 24 h, the infections were monitored by detecting GFP expression under an inverted fluorescence microscope. Cell viability and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were evaluated with the cell proliferation reagent WST-1 (Roche Applied Sciences, Indianapolis, Ind., USA) and the in situ cell death detection kit, POD (Roche Applied Sciences, Indianapolis, Ind., USA) and the in situ cell death detection kit, POD (Roche Applied Sciences), respectively, according to the manufacturer’s instructions. Briefly, after fixing the HUVECs with 4% paraformaldehyde/PBS for 1 h, the
cells were washed, incubated with 3% H₂O₂ in methanol for 10 min, and then permeabilized with 0.1% Triton X-100/0.1% sodium citrate for 2 min on ice. The samples were then rinsed three times with PBS and the TUNEL reaction was performed with TUNEL reaction mix according to the manufacturer's instruction at 37 °C in a humidified chamber for 1 h. After washing, converter-POD and DAB substrate were treated and samples were analyzed by Nikon ECLIPSE E400 light microscope. For DNA fragmentation analysis, the culture medium was removed and centrifuged at 2,500 g for 5 min to collect detached cells. The cell pellet was resuspended in 500 μl of DNA extraction buffer (50 mM Tris, pH 8.0, 20 mM Na₂EDTA, 10 mM NaCl, 1% [w/v] SDS, and 20 μg ml⁻¹ RNase A [Sigma R-5503]) and incubated at 37 °C for 1 h, followed by the addition of proteinase K (Sigma P-2308) to a final concentration of 100 μg ml⁻¹ and incubation at 65 °C for 1 h. The reaction containing DNA was purified once with chloroform/isoamylic alcohol (24:1) and precipitated with 5 M NaCl. The precipitated DNA was electrophoretically separated on a 1% agarose gel containing 1 μg ml⁻¹ ethidium bromide and visualized under ultraviolet transillumination.

**Results**

**Infection of HUVECs with KSHV and Expression of DcR3**

After HUVECs were infected with the recombinant KSHV-BAC36 containing a GFP cassette by low-speed centrifugation [18], the infectivity was measured by monitoring GFP expression under a fluorescence microscope and the ratio of GFP-expressing cells was measured by flow cytometry (fig. 1). Fluorescence microscopy showed GFP expression in the infected cells, and most of the GFP-expressing cells also expressed ORF73 in the nucleus. At 24 h after infection, the overall expression rate was over 60%; a representative figure is shown in figure 1b. To investigate lytic gene expression, immunofluorescence assay (IFA) was performed with anti-ORF73 and anti-ORF59 antibodies at 24 and 48 h after infection. The expression of ORF59, a KSHV lytic gene,
was not detected at 24 h but was detected at 48 h (fig. 1c). Our results are consistent with previous studies which showed that Orf59 mRNA is expressed 16 h after infection and that lytic protein is detected 2 days postinfection [15, 16]. The DcR3 mRNA expression level in KSHV-BAC36 infected HUVECs was tested at different time points by reverse transcription quantitative PCR methods (fig. 2a). DcR3 mRNA was detected 4 h after infection, and a significant increase in expression at 6 to 12 h postinfection and a decrease at 16 h were observed. After 24 h, the expression level of DcR3 increased gradually again. The culture supernatant was also tested for DcR3 expression after KSHV infection (fig. 2b). At 4 h postinfection, DcR3 began to be expressed and the concentration of DcR3 gradually increased until 72 h postinfection. These results indicate that KSHV is one of the factors causing the upregulation of DcR3 in HUVECs and that the expression of DcR3 is regulated differently depending on the length of time after KSHV infection.

Effects of DcR3 in the Early Phase of KSHV Infection

To investigate the effect of DcR3 in KSHV infection, an anti-DcR3 antibody was added to the KSHV-infected HUVECs. After 1 h of centrifugal infection, the virus was removed and EGM-2 containing anti-DcR3 or control IgG was added to the infected cells, followed by 24 h of culture. At 24 h postinfection, a cell proliferation assay showed significant differences in cell viability between the anti-DcR3 and the control IgG-treated groups, especially at antibody concentrations over 0.5 μg ml⁻¹ (fig. 3a). As anti-DcR3 did not show any effects in mock-infected HUVECs, this inhibitory effect was not considered a result of the adverse effect of the anti-DcR3 antibody. Due to the potential presence of growth factors in the EGM-2 culture media, which could inhibit cell death even when DcR3 is blocked, the assay was repeated in serum and supplement-free endothelial basal medium-2 (fig. 3b). The cell viability pattern and the effect of anti-DcR3 were similar to those observed in EGM-2 culture medium, although overall cell viability was low in serum and supplement-free media. These results suggest that DcR3 produced in the early phase of KSHV infection of HUVECs inhibits cell death. Recombinant human TL1A, a ligand for DcR3, was serially diluted from a stock solution of 500 ng ml⁻¹ and the dilutions were applied to KSHV-infected HUVECs in endothelial cell culture media with or without serum and supplements. TL1A showed a close association with cytotoxicity after KSHV infection regardless of the culture media used. Exposure to the recombinant human TL1A enhanced cytotoxic effects in the early phase of KSHV infection of HUVECs but not in the early stages of mock infection of HUVECs, indicating that DcR3 protects against KSHV infection (fig. 4). As the recombinant TL1AL72-L251 used in these experiments has no effect on HUVEC proliferation or apoptosis [15], these results show that DcR3 protects against KSHV infection.

DcR3 Inhibits Apoptosis during the Early Phase of KSHV Infection

To understand the mechanisms underlying the effect of DcR3 on the inhibition of cell death in KSHV-infected HUVECs, two kinds of apoptosis assays were performed, namely the TUNEL staining assay and the DNA ladder
formation assay. As shown in figure 5A, control IgG-treated KSHV-infected HUVECs showed minimal TUNEL-positive staining, whereas anti-DcR3-treated cells displayed a significant proportion of TUNEL-positive apoptotic cells. An evaluation of the rate of apoptosis in anti-DcR3 treated cells was not possible due to the overall poor status of the cells and continuous cell death after infection. The results obtained with the apoptosis assays were consistent with the results of the cell proliferation assay described above. Cells from the same experiments were subjected to a DNA fragmentation assay (fig. 5B). Although DNA ladder formation was minimal in cells treated with control IgG, increased DNA laddering was observed in anti-DcR3-treated cells. Therefore, DcR3 produced by KSHV-infected HUVECs provides a survival advantage during the early phase of KSHV infection through an anti-apoptotic effect.

**Discussion**

Viruses have developed many mechanisms to hijack the metabolic pathways of their hosts for their own benefit and to evade attacks by the immune system. EBV and HTLV-1 use DcR3 to evade the defenses of the immune system during lymphomagenesis, and virus-infected DcR3-expressing lymphoma cells can also be selected during the multistep tumorigenesis process [15]. KSHV,
also known as human herpesvirus 8, is a gammaherpesvirus and the proposed etiologic agent of Kaposi's sarcoma, primary effusion lymphoma, and a subset of multicentric Castleman's diseases [19]. KSHV infects a variety of human cell types, including B, T, endothelial, epithelial, fibroblast, and keratinocyte cells, as well as nonhuman cell types, including owl monkey kidney and baby hamster kidney fibroblast cells, in some cases resulting in the establishment of long-term cultures [20–22]. As Kaposi’s sarcoma is mainly a vascular tumor and the spindle-shaped cells composing the vasculature in Kaposi’s sarcoma express certain endothelial cell markers, it is believed that this type of tumor originates from KSHV-infected endothelial cells. The present study assessed the kinetics of DcR3 mRNA and soluble DcR3 protein expression in KSHV-infected HUVECs. In KSHV-infected HUVECs, DcR3 mRNA expression showed a biphasic expression pattern; the first peak was observed around 10 h postinfection and then decreased around 16 h postinfection. After the viral gene was actively expressed, the expression of DcR3 increased again. The two peaks of expression may be caused by different underlying mechanisms. According to a previous study, little KSHV mRNA is expressed until about 10 h postinfection, after which expression gradually increases. The second increase in DcR3 expression in KSHV-infected HUVECs could be a response to viral replication or to the expression of viral proteins, whereas the first peak occurred before viral genes were actively expressed. Although the exact mechanism of upregulation of DcR3 expression prior to active viral gene expression was not investigated in detail in this study, the first phase of induction could be due to a receptor-mediated event during virus entry. The cellular response to virus entry or the presence of proteins or microRNAs derived from the viral capsid would have an effect on the expression of DcR3.

The results of the present study show that expression of DcR3 has a protective effect against KSHV infection in HUVECs. Exposure of KSHV-infected cells to antagonistic anti-DcR3 antibodies resulted in a cytotoxic effect in over 50% of cells, which TUNEL and DNA fragmentation assays showed was mediated by apoptosis. DcR3 is known to inhibit apoptosis by blocking FasL, LIGHT and TL1A. Although FasL is known to be involved in apoptosis, endothelial cells are resistant to Fas-mediated cell death after exposure to soluble FasL or agonist anti-Fas antibody [23]. Preliminary experiments in the present study did not show an effect of soluble FasL on HUVECs (data not shown). When the expression of TL1A and LIGHT were investigated in KSHV or mock-infected HUVECs, only TL1A mRNA was detected and there was no amplification of LIGHT at postinfection time 24 h (fig. 6a). Therefore, LIGHT would not act on HUVECs in an autocrine manner. As DcR3 was reported to induce cell proliferation, migration, MMP-2 expression, and angiogenesis by neutralizing TL1A autocrine in HUVECs, the increase in the expression of soluble DcR3 during KSHV infection would inhibit apoptosis of HUVECs in a similar way. Although there was no significant difference of TL1A mRNA expression between KSHV- and mock-infected cells (fig. 6b), a recent study reported that most of the TL1A expressed in HUVECs was in an uncleaved membrane-bound form and that a very small amount of TL1A
was expressed as two functionally distinct isoforms of the soluble fragment [15]. Hence, mRNA expression analysis was not helpful for the analysis of the expression of soluble TL1A. As one of the soluble fragments of TL1A has been reported to be an inducer of apoptosis in HUVECs, it is possible that DcR3 blocks this soluble TL1A on HUVECs during the early phase of KSHV infection. Further studies will be required to elucidate the exact mechanism of DcR3-mediated apoptosis inhibition.

Induction of pro-angiogenic and pro-inflammatory cytokines, such as IL-6, Ang-2, MMP-1, MMP-2 and MMP-9, has been described in KSHV-infected HUVECs. These proteins are thought to have roles in the pathogenesis of KSHV-related lesions, such as Kaposi’s sarcoma. Some of these proteins induce angiogenesis by increasing cell invasiveness [24, 25]. DcR3 could protect KSHV-infected endothelial cells by inhibiting apoptosis at the early phase of KSHV infection. One outcome of protecting cell death is to allow more time for the virus to replicate, and make more virions to spread to other cells. Additionally, other paracrine-dependent suppressive effects for apoptosis might also be relevant under in vivo conditions. As one ligand of DcR3 is TL1A, it could affect the angiogenesis of KSHV-infected endothelial cells. DcR3 might have similar effects on the pathogenesis of Kaposi’s sarcoma in the presence of other induced cytokines.

In summary, the present results show that DcR3 was expressed in HUVECs during the early phases of KSHV infection. DcR3 showed a protective effect against virus-mediated cytotoxicity in KSHV-infected HUVECs. These results suggest that DcR3 could play a role in the establishment and maintenance of KSHV infection in HUVECs.
References


